From the perspective of scaling up PSA screening, it may be worth mentioning that the internationalmarket size for prostate cancer diagnostics was estimated at USD 2.2 billion in 2017 and is forecasted to enlarge at a CAGR of 12.3% to reach USD 5.5 billion by 2025 [39]. Here, KLK3 is linked to prostate cancer.